Skip to main content
Top
Published in: Breast Cancer Research 1/2019

Open Access 01-12-2019 | Research article

Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings

Authors: Haojia Li, Jon Whitney, Kaustav Bera, Hannah Gilmore, Mangesh A. Thorat, Sunil Badve, Anant Madabhushi

Published in: Breast Cancer Research | Issue 1/2019

Login to get access

Abstract

Background

Oncotype DX (ODx) is a 12-gene assay assessing the recurrence risk (high, intermediate, and low) of ductal carcinoma in situ (pre-invasive breast cancer), which guides clinicians regarding prescription of radiotherapy. However, ODx is expensive, time-consuming, and tissue-destructive. In addition, the actual prognostic meaning for the intermediate ODx risk category remains unclear.

Methods

In this work, we evaluated the ability of quantitative nuclear histomorphometric features extracted from hematoxylin and eosin-stained slide images of 62 ductal carcinoma in situ (DCIS) patients to distinguish between the corresponding ODx risk categories. The prognostic value of the identified image signature was further evaluated on an independent validation set of 30 DCIS patients in its ability to distinguish those DCIS patients who progressed to invasive carcinoma versus those who did not. Following nuclear segmentation and feature extraction, feature ranking strategies were employed to identify the most discriminating features between individual ODx risk categories. The selected features were then combined with machine learning classifiers to establish models to predict ODx risk categories. The model performance was evaluated using the average area under the receiver operating characteristic curve (AUC) using cross validation. In addition, an unsupervised clustering approach was also implemented to evaluate the ability of nuclear histomorphometric features to discriminate between the ODx risk categories.

Results

Features relating to spatial distribution, orientation disorder, and texture of nuclei were identified as most discriminating between the high ODx and the intermediate, low ODx risk categories. Additionally, the AUC of the most discriminating set of features for the different classification tasks was as follows: (1) high vs low ODx (0.68), (2) high vs. intermediate ODx (0.67), (3) intermediate vs. low ODx (0.57), (4) high and intermediate vs. low ODx (0.63), (5) high vs. low and intermediate ODx (0.66). Additionally, the unsupervised clustering resulted in intermediate ODx risk category patients being co-clustered with low ODx patients compared to high ODx.

Conclusion

Our results appear to suggest that nuclear histomorphometric features can distinguish high from low and intermediate ODx risk category patients. Additionally, our findings suggest that histomorphometric features for intermediate ODx were more similar to low ODx compared to high ODx risk category.
Appendix
Available only for authorised users
Literature
2.
go back to reference Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements. 2009;26(2):1–27 PMID: 19784089.PubMed Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements. 2009;26(2):1–27 PMID: 19784089.PubMed
5.
go back to reference McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W, Pu AT, Kerlin K, White J. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(7):709–15. https://doi.org/10.1200/JCO.2014.57.9029 PMID: 25605856 PMCID: PMC4334775.CrossRef McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W, Pu AT, Kerlin K, White J. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(7):709–15. https://​doi.​org/​10.​1200/​JCO.​2014.​57.​9029 PMID: 25605856 PMCID: PMC4334775.CrossRef
7.
go back to reference Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. JNCI J Natl Cancer Inst. 2013;105(10):701–10. https://doi.org/10.1093/jnci/djt067 PMID: 23641039 PMCID: PMC3653823.CrossRefPubMed Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. JNCI J Natl Cancer Inst. 2013;105(10):701–10. https://​doi.​org/​10.​1093/​jnci/​djt067 PMID: 23641039 PMCID: PMC3653823.CrossRefPubMed
8.
go back to reference Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J. Clinical utility of the 12-gene DCIS score assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Ann Surg Oncol. 2017;24(3):660–8. https://doi.org/10.1245/s10434-016-5583-7 PMID: 27704370 PMCID: PMC5306072.CrossRefPubMed Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J. Clinical utility of the 12-gene DCIS score assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Ann Surg Oncol. 2017;24(3):660–8. https://​doi.​org/​10.​1245/​s10434-016-5583-7 PMID: 27704370 PMCID: PMC5306072.CrossRefPubMed
10.
go back to reference Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995;26(8):873–9 PMID: 7635449.CrossRefPubMed Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995;26(8):873–9 PMID: 7635449.CrossRefPubMed
17.
go back to reference Devore JL. Probability and statistics for engineering and the sciences. Monterey: Cengage Learning; 2011. Devore JL. Probability and statistics for engineering and the sciences. Monterey: Cengage Learning; 2011.
21.
go back to reference Pelckmans K, Suykens JAK, Gestel TV, Brabanter JD, Lukas L, Hamers B, Moor BD, Vandewalle J. LS-SVMlab: a MATLAB/C toolbox for Least Squares Support Vector Machines. Tutorial. Leuven: KULeuven-ESAT. 2002;142:1–2. Pelckmans K, Suykens JAK, Gestel TV, Brabanter JD, Lukas L, Hamers B, Moor BD, Vandewalle J. LS-SVMlab: a MATLAB/C toolbox for Least Squares Support Vector Machines. Tutorial. Leuven: KULeuven-ESAT. 2002;142:1–2.
25.
go back to reference Bhattacharyya A. On a measure of divergence between two statistical populations defined by their probability distributions. Bull Calcutta Math Soc. 1943;35:99–109. Bhattacharyya A. On a measure of divergence between two statistical populations defined by their probability distributions. Bull Calcutta Math Soc. 1943;35:99–109.
27.
go back to reference Al-Garadi MA, Mohamed A, Al-Ali A, Du X, Guizani M. A Survey of Machine and Deep Learning Methods for Internet of Things (IoT) Security. 2018;arXiv preprint arXiv:1807.11023. Al-Garadi MA, Mohamed A, Al-Ali A, Du X, Guizani M. A Survey of Machine and Deep Learning Methods for Internet of Things (IoT) Security. 2018;arXiv preprint arXiv:1807.11023.
28.
go back to reference Longadge R, Dongre S. Class imbalance problem in data mining review. Int J Comput Sci Netw. 2013;2(1). Longadge R, Dongre S. Class imbalance problem in data mining review. Int J Comput Sci Netw. 2013;2(1).
31.
go back to reference Liu Z, Kakudo K, Bai Y, Li Y, Ozaki T, Miyauchi A, Taniguchi E, Mori I. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J Clin Pathol. 2011;64(4):325–9. https://doi.org/10.1136/jcp.2010.083956 PMID: 21296795.CrossRefPubMed Liu Z, Kakudo K, Bai Y, Li Y, Ozaki T, Miyauchi A, Taniguchi E, Mori I. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J Clin Pathol. 2011;64(4):325–9. https://​doi.​org/​10.​1136/​jcp.​2010.​083956 PMID: 21296795.CrossRefPubMed
32.
go back to reference Herrera-Espiñeira C, Marcos-Muñoz C, López-Cuervo JE. Diagnosis of breast cancer by measuring nuclear disorder using planar graphs. Anal Quant Cytol Histol. 1997;19(6):519–23 PMID: 9893907.PubMed Herrera-Espiñeira C, Marcos-Muñoz C, López-Cuervo JE. Diagnosis of breast cancer by measuring nuclear disorder using planar graphs. Anal Quant Cytol Histol. 1997;19(6):519–23 PMID: 9893907.PubMed
33.
go back to reference Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989;63(4):618–24 PMID: 2536582.CrossRefPubMed Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989;63(4):618–24 PMID: 2536582.CrossRefPubMed
36.
go back to reference Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. https://doi.org/10.1056/NEJMoa1804710 PMID: 29860917.CrossRefPubMedPubMedCentral Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. https://​doi.​org/​10.​1056/​NEJMoa1804710 PMID: 29860917.CrossRefPubMedPubMedCentral
Metadata
Title
Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings
Authors
Haojia Li
Jon Whitney
Kaustav Bera
Hannah Gilmore
Mangesh A. Thorat
Sunil Badve
Anant Madabhushi
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2019
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-019-1200-6

Other articles of this Issue 1/2019

Breast Cancer Research 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine